Issuu on Google+

CURRICULUM VITAE Jeffrey C. Fink, M.D., M.S. Associate Professor of Medicine University of Maryland School of Medicine February 6, 2013 Nephrology Division, Department of Medicine University of Maryland School of Medicine, Rm N3W143 22 S. Greene St Baltimore, Maryland 21201 (410) 328-5720 FAX: (410) 328-5685 jfink@medicine.umaryland.edu EDUCATION 1979 – 1983

B.A.

Clark University Worcester, Massachusetts

1983 - 1987

M.D.

Case Western University School of Medicine Cleveland, Ohio

1994 - 1996

M.S.

Master of Science Program Department of Epidemiology School of Public Health and Community Medicine University of Washington Seattle, Washington

MEDICAL TRAINING Internship 1987 - 1988

Residency 1988 - 1990 Fellowship 1993 - 1994

1994 - 1996

Intern in Medicine University of Washington Seattle, Washington Resident in Medicine University of Washington Seattle, Washington Clinical Fellow Division of Nephrology University of Washington Seattle, Washington Research Fellow Division of Nephrology University of Washington Seattle, Washington

CERTIFICATION 1990-2000 Diplomate, American Board of Internal Medicine

1


1996-2006 2000-2010 2000-2014

Diplomate, American Board of Internal Medicine, Nephrology subspecialty Recertified, Diplomate, American Board of Internal Medicine Recertified, American Board of Internal Medicine, Nephrology subspecialty

LICENSURE Maryland, #50777 EMPLOYMENT HISTORY 1990 - 1992

Assistant Professor of Medicine Division of General Internal Medicine, Department of Medicine Tufts University School of Medicine

1992 - 1993

Assistant Professor of Medicine Division of General Internal Medicine, Department of Medicine University of Southern California

1996 -2002

Assistant Professor, Departments of Medicine (primary) and Epidemiology (secondary) Division of Nephrology University of Maryland School of Medicine

2002 – present

Associate Professor, Departments of Medicine (primary) and Epidemiology (secondary) Division of Nephrology University of Maryland School of Medicine

PROFESSIONAL MEMBERSHIP 1990American College of Physicians 1993National Kidney Foundation American Society of Nephrology 1999American Society of Transplantation 2001American Heart Association HONORS and AWARDS 1982 1999 2005

Phi Beta Kappa, Clark University American Society of Nephrology, Carl W. Gottschalk Research Award Fellow, American Society of Nephrology

ADMINISTRATIVE SERVICE Institutional (University of Maryland)

2000-2002 2001 2005-2007 2006-present 2006-present

School of Medicine Dean’s Council Faculty Practice Office, Space Committee Faculty Senate Institutional Review Board GCRC Advisory Committee

2


2008

Director, Baltimore VA Pre-transplant services

Local and National

1992 1997- 2007 2001- 2004 2001- 2002 2001-2002 2002 2002-present 2003-2004 2004-2007 2004-present 2006-present 2006-present 2008 2008 2009 2009 – present 2009 – present 2009 – present

Expert Witness for United States Attorney, U.S. vs. Smushkevich, et al. National Kidney Foundation of Maryland, Medical Advisory Board Mid-Atlantic Renal Coalition, Medical Research Board National Kidney Foundation of Maryland, Grant Review Committee American Society of Nephrology, Clinical Science Committee Editorial Board, American Journal of Kidney Disease National Kidney Foundation, Career Development Grant Review Committee Maryland Kidney Commission National Kidney Disease Education Program, Baltimore Co-Chairman Editorial Board, Journal of the American Society of Nephrology American Society of Nephrology, Chronic Kidney Disease Advisory Committee Paul Teschan Research Fund Grant Reviewer NIDDK Data Safety and Monitoring Board (DSMB) for Clinical Trial of Oral versus IV Iron in CKD Patients (PI Agarwal) NIH Special Emphasis Scientific Review Group Ancillary Studies in the Natural History of Acute Kidney Injury ZDK1 GRB-7 (M1) NIH Scientific Review Group Pilot And Feasibility Grants In Kidney Disease (PAR 06-113) ZRG1 RUS-F S (7/24/08) NIH Scientific Review Group Nephrology and Urology Clinical and Small Business Grants 2009/05 ZRG1 DKUS-G (51) S (4/6-4/7) Associate Editor, American Journal of Kidney Disease Editorial Board, Clinical Nephrology American Society of Nephrology, Clinical Science Committee

TEACHING SERVICE 1996.1998 Attending on Medical Service conducted daily teaching rounds and weekly lectures to 3-5 medical students and 4 residents, 1 month per year 1996-present • Attending on Transplant Service conduct daily teaching rounds 3-4 months per year to 2 residents and 1 nephrology fellow in conjunction with surgery attending • Renal Journal Club lead 3 to 4 one hour conferences per year, attended by 3-4 nephrology fellows • Small Group Leader, Renal Pathophysiology and Therapeutics lead 3 small group sessions per year attended by 5-10 2nd year medical students • Small Group Leader, Cardiovascular Pharmacology lead 2 small group sessions per year attended by 5-10 2nd year medical students

3


1997- present 2000 2000- present 2001-2003 2005 2006 2007- present 2008 2008 2009

Research mentor to Students (Kennedy Gabregiorgish: 1997, Mark Flasar:1998, Yonaton Spotler, 2006) and Residents (Rachel Burdick:1998 , Manoj Reddy: 1999, Daniel Weiner:2000, see publications ) Department of Epidemiology Clinical Epidemiology Seminar 1 hour lecture, 25 students and fellows (July 17) Early Renal Insufficiency Teaching Conference conduct monthly conference attended by 2-3 nephrology fellows and staff Department of Medicine Continuing Medical Education Program (first annual) 1 hour lecture to 50-75 guest physicians (June 18) Ambulatory care conference, University of Maryland 1 hour lecture to 20 residents (July 29) Small group March 31st Acid Base 20 Students Attending on VA Medical Service, One month annually 4 house staff, 4 students Small groups April 1 and 2nd 8-10AM Renal Pathophysiology 20 students per session Research mentor to 2nd yr medical students (Lisa Einhorn, Maureen Moen, see Publications) Renal Pathophysiology and Therapeutics Small groups March 25, 26, 27, April 1 & 3 20 Students per session

GRANT SUPPORT Past July, 1997 – June, 1998

Principal Investigator “Protein Catabolic Rate in the United States” National Kidney Foundation, Maryland Chapter Total award $4000, Total direct cost $4000

July, 1998 – June, 1999

Principal Investigator “How Variable is Achieved Dialysis Adequacy of ESRD Patients” National Kidney Foundation, Maryland Chapter Total award $3250, Total direct cost $3250

July, 1998 – June, 1999

Principal Investigator “Disparity between Maryland and Virginia in Referral of ESRD Patients for Dialysis.” UMB School of Medicine-Pangborn Award Total award $15000, Total direct cost $15000

July 1999 – July, 2000

Principal Investigator “The Relationship Between Creatinine and Mortality in ESRD Patients” UMB School of Medicine-Pangborn Award Total award $15000, Total direct cost $15000

4


Principal Investigator “Chronic Allograft Nephrology: A Single Center Study of its Predictors and Outcomes.” Hoffman-LaRoche Pharmaceuticals Total award $41,300, Total direct cost $34,417 July, 1999 – June, 2001

Principal Investigator “Role of State and Center Effects in Dialysis Adequacy.” American Society of Nephrology- Carl W. Gottschalk Research Award Total Award $150,000, Total direct cost $136,364

June, 01 – June, 06

Co-principal Investigator Principal Investigator: Dr Matthew Weir Registry of Simulect Treated Living Transplant Recipients Novartis Pharmaceuticals Total award-$216,000, Total direct cost $180,000

September, 04- July, 07

Principal Investigator “Center Effects Influence on Anemia and mortality” NIH/NIDDK 1 R21 DK064126-01A1 Total award $200,000 Direct cost $148,000

September, 03- August, 07

Director, Kidney Disease Research Core Project EXPORT- Comprehensive Centers in Health Disparities NIH/NCMHD 1P60 MD000532-01 (Wilson) Total award: $400,000, Direct cost $ 400,000

May, 03- June, 08

Principal Investigator Relationship Between Tobacco and Kidney Disease Maryland Cigarette Restitution Fund Total award $235,000 Direct cost $235,000

Current Oct, 01- Sept, 11

Site Investigator Chronic Renal Insufficiency Cohort Study NIH NIDDK UO1, DK01-005 (Appel, JHU) Total award (to site) $1,989,999, Total direct cost (to site) $1,639,923

Sept, 05-July, 10

Research Mentor (to Dr Afshin Parsa) NIH/NCRR 5K12 RR023250 (Shuldiner) Clinical Research Career Development Award Direct cost (to mentor) $5000 annually

July 06-June, 08

Principal Investigator Quality of anemia management and its outcome in the VA Amgen Total award $250,00 Direct cost $198,000

5


August, 07- July, 09

Principal Investigator Effect of practice guidelines on care of chronic kidney disease in the VHA NIDDK 1R21DK075675-01A1 Total award $250,000, Direct cost $172,000

PUBLICATIONS Refereed 1. Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, Townsend RR, Xie D, Cifelli D, Cohan J, Fink JC, Fischer MJ, Gadegbeku C, Hamm LL, Kusek JW, Landis JR, Narva A, Robinson N, Teal V, and Feldman HI on behalf of the Chronic Renal Insufficiency Cohort Study Group. The Chronic Renal Insufficiency Cohort (CRIC) Study: Baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol 2009 (epub June 18).

2. Einhorn LM, Zhan M, Hsu VD, Walker L, Moen MF, Seliger SL, Weir MR, Fink JC. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009 ;169(12):11561162

3. Moen MF, Zhan M, Hsu VD, Walker L, Einhorn LM, Seliger SL, Fink JC. The frequency and significance of hypoglycemia in chronic kidney disease. Clin J Am Soc Nephrol May 2009 4. Fink JC, Brown J, Hsu VD, Seliger SL, Walker L, Zhan M. CKD as an under-recognized threat to patient safety. Am J Kidney Disease 2009 53(4):681-8. 5. Semba RD, Ferrucci L, Fink JC, Sun K, Beck J, Dalal M, Guralnik JM, Fried LP. Advanced Glycation End Products and Their Circulating Receptors and Level of Kidney Function in Older Community-Dwelling Women. Am J Kidney Dis 2009 53: 51-8. 6. Semba RD, Fink JC, Sun K, Bandinelli S, Guralnik JM, Ferrucci L. Carboxymethyl-lysine, an advanced glycation end product, and decline of renal function in older community-dwelling adults. Eur J Nutr. 2009 Feb;48(1):38-44

7. Xie D, Joffe MM, Brunelli SM, Beck G, Chertow GM, Fink JC, Greene T, Hsu CY, Kusek JW, Landis R, Lash J, Levey AS, O'Conner A, Ojo A, Rahman M, Townsend RR, Wang H, Feldman HI. A Comparison of Change in Measured and Estimated Glomerular Filtration Rate in Patients with Nondiabetic Kidney Disease. Clin J Am Soc Nephrol 2008 Sep;3(5):1332-8 8. Seliger SL, Zhan M, Hsu VD, Walker L, Fink JC. Chronic Kidney Disease Adversely Influences Patient Safety. J Am Soc Nephrol. 2008 Dec;19(12):2414-9 9. Xie, D, Joffe MM, Brunelli SM, Beck G, Chertow GM, Fink JC, Greene T, Hsu CY, Kusek J, Landis J, Landis R, Lash J, Levey AS, O’Conner A, Ojo A, Rahman M, Townsend RR, Wang H, Feldman HI. A comparison of change in measured and estimated glomerular filtration rate in patients with nondiabetic kidney disease, Clin J Am Soc Nephrol 2008; 3:1332-8

6


10. Fink JC. Do you need to stay in school to get a kidney transplant? Am J Kidney Dis. 2008 May;51(5):717-8

11. Dilsizian V, Fink JC. Deleterious effect of altered myocardial fatty acid metabolism in kidney disease. J Am Coll Cardiol. 2008;51:146-8. 12. Seliger SL, Katzel LI, Fink JC, Weir MR, Waldstein SR. Renal function and cardiovascular response to mental stress. Am J Nephrol. 2008; 28:304-10 13. Spolter YS, Seliger SL, Zhan M, Hsu VD, Walker LD, Fink JC. The relationship between dialysis performance measures: adequacy and anemia management. Am J Kidney Dis 2007; 50: 774-781.

14. Vessal G, Wiland AM, Philosophe B, Fink JC, Weir MR, Klassen DK. Early steroid withdrawal in solitary pancreas transplantation results in equivalent graft and patient survival compared with maintenance steroid therapy. Clin Transplant. 2007; 21:491-7 15. Jones-Burton C, Vessal G, Brown J, Dowling TC, Fink JC. Urinary Cotinine as an Objective Measure of Cigarette Smoking in Chronic Kidney Disease. Nephrol Dial Transplant 2007; 22:1950-4. 16. Jones-Burton C, Seliger SL, Scherer R, Mishra S, Brown J, Weir M, Fink JC. Cigarette smoking and incident chronic kidney disease: a systematic review. Am J Neprhol . 2007;27:342-35 17. Fink JC, Hsu VD, Zhan M, Walker LD, Mullins CD, Jones-Burton C, Langenberg P, Seliger SL. Center effects in anemia management of dialysis patients. J Am Soc Nephrol 2007; 18: 646-653. 18. Jones-Burton C, Mishra SI, Fink JC, Brown J, Gossa W, Bakris GL, Weir MR “An In-depth Review of the Evidence Linking Dietary Salt Intake and Progression of Chronic Kidney Disease” Am J Nephrol 2006 Jun 9;26(3):268-275

19. McGregor JC, Perencevich EN, Furono JP, Langenberg P, Flannery K, Zhu J, Fink JC, Bradham DD, Harris AD. Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections. J Clin Epidemiol 2006; 59:1266-73 20. Khan IA, Fink J, Nass C, Chen H, Christenson R, deFilippi CR. N-terminal pro-B-type natriuretic Peptide and B-type natriuretic Peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol 2006; 97: 1530-1534. 21. Jones –Burton C, Seliger SL, Brown J, Stackiewicz L, Doren Hsu V, Fink JC Racial variations in erythropoietic response to epoetin alfa in chronic kidney disease and the impact of smoking. Nephrol Dial Transplant 2005; 20: 2739-2745 22. Ble A, Fink JC, Woodman RC, Klausner MA, Windham BG, Guralnik JM, Ferrucci L. Renal function, erythropoietin and anemia of older persons: the InChianti Study. Arch Intern Med 2005; 165: 2222-2227. 23. Mishra SI, Jones-Burton C, Fink JC, Brown J, Bakris GL, Weir MR. Does dietary salt increase the risk of progression of kidney disease? Curr Hypertens Rep 2005; 7: 385-391. 24. Jones-Burton C, Brown J, Miranda M, Passmore SR, Royak Schaler R, Fink JC “Awareness of the Association Between Smoking and Kidney Disease among African-Americans” JAAMP 2005;16:15-

7


20 25. Lu WX, Jones-Burton J, Zhan M, Salzber DJ, Moore Jr J, Fink JC. Survival Benefit of Recombinant Human Erythropoietin Administration prior to Onset of End-Stage Renal Disease: Variations across Surrogates for Quality of Care and Time Nephron Clin Pract 2005; 101: c79-c86 26. deFilippi C, Fink JC, Nass CM, Loukonen D; Chen C, Christenson R; Pro-B-type natriuretic peptide predicts coronary disease and left ventricular hypertrophy in asymptomatic chronic kidney disease patients not requiring renal replacement therapy. Am J Kidney Dis 2005: 46: 35-44. 27. Wali RK, Wang GS, Gottlieb SS, Bellumkonda L, Hansalia R, Ramos E, Drachenberg C, Papadimitriou J, Brisco MA, Blahut S, Fink JC, Fisher ML, Bartlett ST, Weir MR. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Card 2005 45: 1051-1060. 28. McGregor JC, Kim PW, Perencevich EN, Bradham DD, Furuno JP, Kaye KS, Fink JC, Langenberg P, Roghmann MC, Harris AD. The Utility of the Chronic Disease Score and Charlson Comorbidity Index as Comorbidity Measures for use in Epidemiologic Studies of Antibiotic-Resistant Organisms. Am J Epidemiol. 2005; 161: 483-493. 29. Weir MR and Fink JC. Salt Intake and Progression of Chronic Kidney Disease: An overlooked modifiable exposure? A Commentary. Am J Kidney Dis 2005; 45: 176-188. 30. Jones-Burton C, Brown J, Miranda M, Passmore S, Royak-Schlaer R, Fink JC. Awareness of the association between smoking and kidney disease among African Americans. JAAMP; 16:34-39, 2005 31. Weir MR, Blahut SA, Drachenberg C, Young C, Papademitriou J, Klassen DK, Cangro CB, Bartlett ST, Fink JC. Late Calcineurin Inhibitor Withdrawal As A Strategy to Prevent Graft Loss in Patients with Suboptimal Kidney Transplant Function. Am J Nephrol 2004; 24: 379-386. 32. Provenzano R, Garcia-Mayol L, Suchinda P, Von Hartitzsch B, Woollen SB, Zabaneh R, Fink JC. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 2004; 61: 392-405. 33. Harris AD, Bradham DD, Baumgarten M, Zuckerman IH, Fink JC, Perencevich EN. The use and interpretation of quasi-experimental designs in infectious diseases. Clin Infect Dis 2004; 38:1586-91. 34. Wiland AM, Fink JC, Weir MR, Philosophe B, Blahut S, Weir MR Jr, Copenhaver B, Bartlett ST. Should Living Unrelated Renal Transplants Receive Antibody Induction? Results of a Clinical Experience Trial. Transplantation 2004; 77: 422-425. 35. Ramos E, Drachenberg CB, Portocarrero M, Wali R, Klassen DK, Fink JC, Farney A, Hirsch H, Papadimitriou JC, Cangro CB, Weir MR, Bartlett ST, BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. Clin Transpl 2003: 143-153 36. Gehr T, Bender F, Fink J, Light P, Elliott K, Shield C, Turner M, Mays C, Parrish J, Armistead N. Improving adequacy of peritoneal dialysis in ESRD Network 5. Adv Perit Dial 2003; 19: 86-92. 37. Feldman, HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, et al., The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol; 2003; 14: S148S153.

8


38. Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, Karyekar CS, Eddington ND Weir MR, Henrich WL. Characterization of hepatic cytochrome P4503A in patients with end-stage renal disease. Clin Pharm Therap 2003; 73: 427-434. 39. Fink JC, Zhan M, Blahut SA, Soucie M, McClellan WM. Measuring the efficacy of a quality improvement program in dialysis adequacy with changes in center effects. J Am Soc Nephrol 2002; 39 2338-2344. 40. Ramos E, Drachenberg CB, Papadimitriou JC, Hamze O, Fink JC, Klassen DK, Drachenberg RC, Wiland A, Wali R, Cangro CB, Schweitzer E, Bartlett ST, Weir MR. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002; 13: 214-2151. 41. Fink JC, Onuigbo MA, Blahut SA, Christenson RH, Mann D, Bartlett ST, Weir MR. Pre-transplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: a pilot case-control study. Am J Kidney Disease 2002: (in press). 42. Fink JC, Blahut BA, Weir MR. Optimal strategies for modeling the reciprocal of creatinine versus time in renal transplant recipients and patients with native chronic kidney disease. Am J Kidney Dis 2002; 39: (in press). 43. Fink JC, Blahut BA, Weir MR, Sawyer R, Henrich WL, Hise MK. The inevitability of renal function loss in patients with hypercreatinemia. Am J Nephrol 2001; 21:386-389. 44. Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and angiotensin converting enzyme inhibitors to alleviate lower extremity edema due to dihydropyridine calcium channel antagonists. Am J Hypertens 2001; 14: 963968. 45. Stern JM, Sullivan KM, Ott SM, Seidel K, Fink JC, Longton G, Sherrard DJ. Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant 2001; 7: 257-264 46. Weir MR, Ward MT, Blahut SA, Klassen DK, Cangro CB, Bartlett ST, Fink JC. The long term impact of calcineurin inhibitor reduction or discontinuation in patients with declining kidney function due to chronic allograft nephropathy. Kidney Int 2001; 59: 1567-1573. 47. Fink JC, Rochussen J, Blahut SA, Reddy M, Light PD. The use of erythropoietin prior to the initiation of dialysis and its impact on mortality in new end stage renal disease patients. Am J Kidney Dis 2001; 37: 348-355. 48. Fink JC, Blahut SA, Briglia AE, Gardner JF, Light PD. The effect of center versus patient-specific factors on variations in dialysis adequacy. J Am Soc Nephrol 2001; 12: 164-169. 49. Jacobs SC, Cho E, Dunkin, BJ, Flowers JL, Schweitzer E, Cangro C, Fink J, Farney A, Philosophe B, Jarrell B, Bartlett ST. Laparoscopic live donor nephrectomy: the University of Maryland 3-YEAR experience. J Urol 2000; 164:1494-1499. 50. Stehman-Breen CO, Miller L, Fink J, Schwartz SM. Preeclampsia and premature labor among women with hematuria. Paediatric and Perinatal Epidemiology 2000; 14:136-140.

9


51. Fink JC, Gardner JF, Armistead NC, Turner MS, Light PD. Within center correlation in dialysis adequacy. J Clin Epidemiology 2000; 53: 79-85. 52. Fink JC, Burdick RA, Kurth S, Armistead N, Turner M, Shickle L, Light PD. The significance of serum creatinine values in incident end stage renal disease patients. Am J Kidney Dis 1999; 34: 694701. 53. Drachenberg CB, Beskow CO, Cangro CB, Bourquin PM, Simsir A, Fink J, Weir MR, Klassen DK, et al. Human polyoma virus in renal allograft biopsies: morphological findings and correlation with urine cytology. Human Pathology 1999; 30, 970-977. 54. Passalacqua JA, Wiland AM, Fink JC, Bartlett ST, Evans DA, Keay S. Increased incidence of postoperative infections associated with peritoneal dialysis in renal transplant recipients. Transplantation 1999; 68:535-540. 55. Drachenberg CB, Klassen DK, Weir MR, Wiland A, Fink JC, Bartlett ST, Cangro CB, Blahut S, Papadimitriou. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 1999; 68:396-402. 56. Weir MR and Fink JC. Post-transplant Diabetes Mellitus: risks versus benefits with current immunosuppressive medications. Am J Kidney Dis 1999 34:1-14. 57. Nogueira JM, Cangro CB, Fink JC, Klassen DK, Gardner J, Schweitzer E, Wiland A, Flowers J, Jacobs S, Cho E, Philosophe B, Bartlett ST, Weir MR. A comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. Transplantation 1999; 67:722-728. 58. Weir MR, Fink JC, Hanes DS, Gardner J, Klassen DK, Cangro C, Schweitzer E, Bartlett ST. Chronic allograft nephropathy: effect of cyclosporine reduction and addition of mycophenolate mofetil on progression of renal disease. Transplant Proceedings, 1999; 31: 1296-1287. 59. Drachenberg CB, Papadimitriou JC, Klassen DK, Weir MR, Cangro CB, Fink JC, Bartlett ST. Chronic pancreas allograft rejection: morphologic evidence of progression in needle biopsies and proposal of a grading scheme. Transplantation Proceedings, 1999; 31:614. 60. Fink JC, Armistead N, Turner M, Gardner J, Light P. Hemodialysis adequacy in Network 5: disparity between states and the role of center effects. Am J Kidney Dis, 1999; 33:97-103. 61. Papadimitriou JC, Drachenberg CB, Wiland A, Klassen DK, Fink J, Weir MR, Cangro C, EJ Schweitzer, Bartlett ST. Histologic grading of acute allograft rejection in pancreas needle biopsy. Transplantation, 1999; 66: 1741-1745. 62. Fink JC, Schwartz SM, Bennedetti TJ, Stehman-Breen CO. Increased Risk of Adverse Maternal and Fetal Outcomes Among Women With Renal Disease. Pediatric and Perinatal Epidemiology. 1998;12:277-287. 63. Schweitzer EJ, Yoon S, Fink J, Wiland A, Anderson L, Kuo PC, Lim JW, Johnson LB, Farney AC, Weir MR, Bartlett ST. Mycophenolate Mofetil reduces the risk of acute rejection less in AfricanAmerican than in Caucasian kidney recipients. Transplantation 1998; 65:242-248. 64. Fink JC, Leisenring WM, Sherrard DJ, Weiss NS. Risk factors for avascular necrosis following bone marrow transplantation: a case control study. Bone 1998; 22:67-71.

10


65. Roghmann MC, Fink JC, Polish L, Maker T, Brewrink J, Morris JG, Light PD. Colonization with Vancomycin-resistant enterococci in chronic hemodialysis patients. Am J Kidney Dis, 1998; 32:254257. 66. Weir MR, Anderson L, Fink JC, Gabregiorgish K, Schweitzer EJ, Hoehn-Saric E, Klassen DK, Cangro CB, Johnson LB, Kuo PC, Lim JY, Bartlett ST. A novel approach to the treatment of chronic allograft nephropathy. Transplantation, 1997; 64:1706-1710. 67. Fink JC, Cooper MA, Zager RA: Hemodialysis induces tubular injury in patients with acute renal failure. Renal Failure, 1996; 18: 947-949. 68. Fink JC, Cooper MA, Burkhart KM, McDonald GB, Zager RA. Marked Enzymuria Following Bone Marrow Transplantation: a Correlate of Veno-occlusive Disease Induced Hepatorenal Syndrome. J Am Soc Nephrol 1995; 6:1655-1660. 69. Fink JC, Schmid CH, Selker HP. A Decision Aid for Referring Patients with Systolic Murmurs for Echocardiography. J Gen Int Med 1994; 9:479-484. 70. Politster PE, Powell SH, Fink JC. New method for reporting the source of abnormal activities of LDH in serum. Clinical Chemistry 1986; 32:1517-1524. Non-refereed publications and chapters 1. Fink JC. Do you need to finish school to get a kidney transplant? Am J Kidney Disease 2008; 51: 717-718. 2. Dilsizian V, Fink JC. Deleterious effect of altered myocardial fatty acid metabolism in kidney disease. JACC 2008; 51:146-148. 3. Fink JC. Current outcomes and quality of care of dialysis patients. Chapter 43, Principles and Practices of Dialysis, Fourth Edition, ed. Henrich WL , 2008 (in press) 4. Fink JC. Current outcomes of dialysis patients. Chapter 40, Principles and Practice of Dialysis Third Edition, ed by Henrich WL, 2003 5. Fink JC, Henrich WL. The outcome of the urban renal patient: The importance of social factors and center effects. Semin Nephrol 2001; 21: 356-361. 6. Fink JC, Henrich WL. How important is volume excess in the etiology of hypertension in dialysis patients. Semin Dialysis 1999 12: 303-304. 7. Fink JC, Tucker JC. The artificial heart. Health Matrix 1985. Selected abstract publications 1. Fink JC, Blahut SA, Weir MR. Is Renal transplantation adequate treatment for the anemia of renal disease? J Am Soc Nephol 2001; 12: 887A.

11


2. Oniquibo M, Blahut SA, Christenson R, Weir MR, Guitterrez M, Fink JC. Pre-transplant C-reactive protein as a predictor of chronic allograft nephropathy: a case-control study. Am J Transplant 2001; 1: 290A. 3. Fink JC, Blahut SA, Weir MR. Small area variations in erythopoietin use prior to initiation of dialysis in Network 5. J Am Soc Nephrol 2000; 11: 145A. 4. Fink JC, Blahut SA, Light PD, McClellan WM. Assessing the impact of a quality improvement effort on dialysis adequacy by measuring changes in center effects. J Am Soc Nephrol 2000; 11: 146A. 5. Fink JC, Blahut SA, Light PD. The use of erthyropoietin prior to the initiation of dialysis and its impact on mortality. J Am Soc Nephrol 2000; 11: 146A. 6. Salmanullah M, Sawyer R, Henrich WL, Weir MR, Fink JC, Hise MK. The natural history of an elevated creatinine in a VA population. J Am Soc Nephrol 2000; 11: 164A. 7. Fink JC, Blahut SA, Briglia AE, Gardner JF, Light PD. The effect of center versus patient-specific factors on variations in dialysis adequacy. J Am Soc Nephrol 2000; 11: 230A. 8. Fink JC, Blahut SA, Weir MR. Geomapping to assess small area variations in transplantation rates as an initial renal replacement therapy. Transplantation 2000; 69; S116. 9. Weir MR, Traver M, Blahut SA, Klassen DK, Cangro CB, Bartlett ST, Fink JC. The long-term impact of calcineurin inhibitor reduction or discontinuation in patients with declining kidney function due to chronic allograft nephropathy. Transplantation 2000; 69, S163. 10. Philosophe B, Fink JC, Wiland AM, Farney AC, Schweitzer EJ, Colonna JO, Jarrell BE, Krishnamurthi V, Bartlett ST. Low kidney rejection rates with basiliximab induction and delayed introduction of tacrolimus for patients with delayed graft function. Transplantation 2000; 69, S259. 11. Fink JC, Wiland AM, Philosophe B, Blahut SA, Rocchusen JR, Wali RK, Weir MR. The effect of Prograf compared to Neoral on glycemic trends after renal transplantation. Transplantation 2000; 69, S325. 12. Fink JC, Wiland AM, Rocchusen JR, Drachenberg CB, Papadimitriou JP. The increased incidence of BK Polyoma virus in renal transplant recipients treated with Prograf. Transplantation 2000; 69, S385. 13. Wiland AM, Fink JC, Philosophe B, Farney A, Schweitzer EJ, Colonna JO, Weir MR, Bartlett ST. Cost effective measures to administer Thymoglobulin for induction therapy in pancreas transplant recipients. Transplantation 2000; 69; S408. 14. Wiland AM, Fink JC, Philosophe B, Farney AC, Schweitzer EJ, Colonna JO. Weir MR, Bartlett ST. Experience with Thymoglobulin induction therapy in pancreas transplant recipients. Transplantation 2000; 69; S408. MAJOR INVITED LECTURES Jan 26, 2001

“Anemia of Chronic Kidney Disease� University of Virginia Renal Rounds

12


April 25, 2001

May 4, 2001

June 18, 2001 August 13, 2002

January 15, 2003 February 19, 2003 August 27, 2003 October 1, 2003 November 5, 2003

June 9, 2004 July 2, 2004

June 11, 2004

October 28, 2004

June 30, 2005

8-10 physicians in attendance from renal division “Benefits of Epoetin alfa in Treating Anemia of Chronic Kidney Disease” MCP-Hahnemann CME Program 50 physicians in attendance including faculty and housestaff from the institution “Benefits of Epoetin alfa in Treating Anemia of Chronic Kidney Disease” Easton Memorial Hospital Grand Rounds 12 physicians from the hospital in attendance “Anemia of Chronic Kidney Disease” Virginia Assoc. of Family Practice Physicians, Annual Meeting 100 family practice physicians in attendance “Epidemiology of polyomovirus infection in transplantation” NIH, NIAID Scientific Advisory Conference, Bethesda, Maryland 25 physician attendees “Polyomavirus infection in renal transplantation” University of Pennsylvania, Transplant Grand Rounds 15 Physicians in attendance “Polyomavirus infection in renal transplantation” Washington Hospital Center, Transplant Grand Rounds 20 Physicians in attendance “Managing Chronic Kidney Disease” Perry Point VA Medical Center, Medical Grand Rounds 20 Physicians in attendance “Managing Chronic Kidney Disease” Washington VA Medical Center, Nephrology Rounds 15 Physicians in attendance “Analgesic Nephropathy: recommendations for warning labels” Staff members of US Senate Government Affairs Committee Washington DC 10 Senate staffers present “Clinical care of Chronic Kidney Disease” University of Maryland, Department of Medicine CME program 100 physicians present “Clinical care of Chronic Kidney Disease” University of Maryland Department of Family Practice CME program 100 physicians present “Baltimore Coalition activities” National Kidney Disease Education Program, NIH Steering Committee meeting 30 physicans and attendees present “Benefits of a Chronic Kidney Disease clinic” American Society of Nephrology, Renal Week St Louis, Missouri 75 physicians in attendance “Chronic Kidney Disease Management in primary care” Ohio State University Medical Grand Rounds 60 physicians in attendance

13


January 11. 2006 March 15, 2006

April 12, 2006

October 3, 2006

October 21, 2006

October 27, 2006

December 6, 2006

June 2, 2007

October 24, 2007

November 3, 2007

November 19, 2007 and

“Management of Chronic Kidney Disease” Mercy Medical Center, Baltimore 50 physicians in attendance “Center effects in hemodialysis” Mid-Atlantic Nephrology Young Investigators Forum Baltimore, MD 25 physicians in attendance “Chronic Kidney Disease management: same old swan song?” National Capital Nephrology Forum National Naval Medical Center, Bethesda MD 25 physicans in attendance “Promoting the Partnership” Symposium on Transplant and Dialysis Center Relationships: Maryland Commission on Kidney Disease UMBC Technology Center 75 Health Care Providers in Attendance “Chronic Kidney Disease” University of Maryland Mini-Medical School College of Southern Maryland 15 participants “Chronic kidney disease management: same old swan song?” Grand rounds Uniformed Services University of Health Sciences Andrews Air Force Base 50 participants “Chronic kidney disease management: same old swan song?” Renal Grand Rounds JHU-Bayview Medical Center 20 participants “Kidney Disease” University of Maryland Statewide Health Network Heritage United Church of Christ Baltimore, Md. 35 attendees present “Irreversible Renal Failure: Challenges and Considerations with Dialysis and Transplantation” Learning Institute for Management of Chronic Kidney Disease Boston, Massachusetts 40 attendees present “View from a CRIC (Chronic Renal Insufficiency Cohort Study) Clinical Center” Chronic Kidney Disease-Japanese CRIC meeting at the American Society of Nephrology conference San Francisco, California 40 attendees present “The Relationship between Smoking and Chronic Kidney Disease (CKD): Developing Evidence Using Biological Epidemiological Methods” University of Md. Statewide Health Network Baltimore, Md. 100 physicians and attendees present

14


December 5, 2007 January 23, 2008

Novermber 6, 2008

May 27, 2009

“Update on Chronic Kidney Disease” University of Maryland Family Practice Grand Rounds 35 participants “Chronic Kidney Disease and Patient Safety” Renal Disease Interest Group Welch Center, Johns Hopkins University 20 participants “Natuiretic peptides in ESRD American Society of Nephrology Annual Meeting Philadelphia, PA 300 participants “Disease specific safety indicators in CKD” Renal Disease Interest Group Welch Center, Johns Hopkins University 20 participants

MAJOR RESEARCH INTERESTS Clinical epidemiology of chronic kidney disease and end stage renal disease.

15


http://medschool.umaryland.edu/facultyresearchprofile/uploads/2c83831d6259481cbb5a5927c51034da